Can Necitumumab be used after bevacizumab resistance?

Necitumumab and bevacizumab ( Bevacizumab) are two different drugs. They belong to different types of targeted therapy drugs and have different mechanisms of action. Nexituzumab is a second-generation human monoclonal antibody that has shown promise in the treatment of squamous non-small cell lung cancer based on results from the SQUIRE trial and has been approved by the Food and Drug Administration in the United States when used in combination with cisplatin and gemcitabine as first-line treatment.

Bevacizumab is an antibody drug against vascular endothelial growth factor (VEGF). It is mainly used to treat various cancers, such as colorectal cancer, lung cancer, etc. If a patient develops resistance to bevacizumab, it means that bevacizumab is less effective or ineffective in treating them. In this setting, the appropriateness of using nexituzumab needs to be determined on a case-by-case basis. Nexituzumab is mainly used for the treatment of non-small cell lung cancer and may not be suitable for other types of cancer. Common adverse events include rash and hypomagnesemia, but when combined with other drugs, diarrhea, fatigue, anorexia, epistasis, neutropenia, and stomatitis are common.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.